Literature DB >> 32138852

The Changing Face of Infection, Diagnosis, and Management in the United Kingdom.

Syed S Ahmed1, Khaled M Yaghmour2, Fares S Haddad2.   

Abstract

Prosthetic joint infection is still a rare but devastating complication following total hip and knee arthroplasty. The incidence of prosthetic joint infection ranges from 2% to 4% in primary procedures as opposed to nearly 20% in revisions. The challenges that arise here include mainly diagnostic uncertainty, management in immunocompromised patients, recurrent infection, infection around a well-fixed implant, and substantial bone loss, and require careful preoperative assessment and well-defined management plans. This article summarizes recent developments in the diagnosis and management of this increasingly prevalent issue specifically focusing on outcomes following debridement, antibiotics, and implants retention and one-stage revision procedures.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dair; Diagnosis; One stage; Prosthetic joint infection; Two stage

Year:  2020        PMID: 32138852     DOI: 10.1016/j.ocl.2019.12.003

Source DB:  PubMed          Journal:  Orthop Clin North Am        ISSN: 0030-5898            Impact factor:   2.472


  2 in total

1.  One-year infection control rates of a DAIR (debridement, antibiotics and implant retention) procedure after primary and prosthetic-joint-infection-related revision arthroplasty - a retrospective cohort study.

Authors:  F Ruben H A Nurmohamed; Bruce van Dijk; Ewout S Veltman; Marrit Hoekstra; Rob J Rentenaar; Harrie H Weinans; H Charles Vogely; Bart C H van der Wal
Journal:  J Bone Jt Infect       Date:  2021-01-27

2.  Antimicrobial peptides in human synovial membrane as (low-grade) periprosthetic joint infection biomarkers.

Authors:  Ingo J Banke; Niko Stade; Peter M Prodinger; Jutta Tübel; Alexander Hapfelmeier; Rüdiger von Eisenhart-Rothe; Martijn van Griensven; Hans Gollwitzer; Rainer Burgkart
Journal:  Eur J Med Res       Date:  2020-08-17       Impact factor: 2.175

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.